Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
We report the course of a patient with severe autoimmune neutropenia in whom only transient responses occurred with corticosteroids, antilymphocyte globulin and granulocyte-colony stimulating factor, and who was resistant to treatment with azathioprine, cyclosporin and intravenous immunoglobulin. A 10 d course of intravenous Campath-1H monoclonal resulted in a sustained haematological response. The long-lasting effect of Campath-1H may be due to its remarkable ability to induce a profound and prolonged peripheral blood T lymphopenia.
Killick
S B
SB
Department of Haematology, St George's Hospital Medical School, London.
Marsh
J C
JC
Hale
G
G
Waldmann
H
H
Kelly
S J
SJ
Gordon-Smith
E C
EC
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000628:therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007958:Leukocyte Count; D008875:Middle Aged; D009503:Neutropenia / Q000628:therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab